516 related articles for article (PubMed ID: 36627445)
1. RNA splicing dysregulation and the hallmarks of cancer.
Bradley RK; Anczuków O
Nat Rev Cancer; 2023 Mar; 23(3):135-155. PubMed ID: 36627445
[TBL] [Abstract][Full Text] [Related]
2. Alternative RNA splicing in tumour heterogeneity, plasticity and therapy.
Öther-Gee Pohl S; Myant KB
Dis Model Mech; 2022 Jan; 15(1):. PubMed ID: 35014671
[TBL] [Abstract][Full Text] [Related]
3. An intricate rewiring of cancer metabolism via alternative splicing.
Temaj G; Chichiarelli S; Saha S; Telkoparan-Akillilar P; Nuhii N; Hadziselimovic R; Saso L
Biochem Pharmacol; 2023 Nov; 217():115848. PubMed ID: 37813165
[TBL] [Abstract][Full Text] [Related]
4. Alternative splicing and cancer: a systematic review.
Zhang Y; Qian J; Gu C; Yang Y
Signal Transduct Target Ther; 2021 Feb; 6(1):78. PubMed ID: 33623018
[TBL] [Abstract][Full Text] [Related]
5. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
Venkataramany AS; Schieffer KM; Lee K; Cottrell CE; Wang PY; Mardis ER; Cripe TP; Chandler DS
Ann Oncol; 2022 Jun; 33(6):578-592. PubMed ID: 35339647
[TBL] [Abstract][Full Text] [Related]
6. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
[TBL] [Abstract][Full Text] [Related]
7. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski LM; Leclair N; Anczuków O
Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
[TBL] [Abstract][Full Text] [Related]
8. RNA Splicing and Cancer.
Wang E; Aifantis I
Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory Gene-Splicing Dysregulation in Tumorigenesis: Unmasking the Complexity.
Maebele LT; Mulaudzi TV; Yasasve M; Dlamini Z; Damane BP
Molecules; 2023 Aug; 28(16):. PubMed ID: 37630236
[TBL] [Abstract][Full Text] [Related]
10. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
11. Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing.
Zerbe LK; Pino I; Pio R; Cosper PF; Dwyer-Nield LD; Meyer AM; Port JD; Montuenga LM; Malkinson AM
Mol Carcinog; 2004 Dec; 41(4):187-96. PubMed ID: 15390079
[TBL] [Abstract][Full Text] [Related]
12. Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics.
Peng Q; Zhou Y; Oyang L; Wu N; Tang Y; Su M; Luo X; Wang Y; Sheng X; Ma J; Liao Q
Mol Ther; 2022 Mar; 30(3):1018-1035. PubMed ID: 34793975
[TBL] [Abstract][Full Text] [Related]
13. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
14. Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer.
Kitamura K; Nimura K
Cells; 2021 Apr; 10(4):. PubMed ID: 33923658
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.
Sahin I; George A; Seyhan AA
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769221
[TBL] [Abstract][Full Text] [Related]
16. Splicing and cancer: Challenges and opportunities.
Coltri PP; Dos Santos MGP; da Silva GHG
Wiley Interdiscip Rev RNA; 2019 May; 10(3):e1527. PubMed ID: 30773852
[TBL] [Abstract][Full Text] [Related]
17. Splicing in oncogenesis and tumor suppression.
Kaida D; Schneider-Poetsch T; Yoshida M
Cancer Sci; 2012 Sep; 103(9):1611-6. PubMed ID: 22691055
[TBL] [Abstract][Full Text] [Related]
18. Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets.
Wang Y; Bao Y; Zhang S; Wang Z
Sci China Life Sci; 2020 Apr; 63(4):469-484. PubMed ID: 32086672
[TBL] [Abstract][Full Text] [Related]
19. HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395.
Sun G; Zhou H; Chen K; Zeng J; Zhang Y; Yan L; Yao W; Hu J; Wang T; Xing J; Xiao K; Wu L; Ye Z; Xu H
J Exp Clin Cancer Res; 2020 Jun; 39(1):116. PubMed ID: 32560659
[TBL] [Abstract][Full Text] [Related]
20. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis.
Liu F; Dai M; Xu Q; Zhu X; Zhou Y; Jiang S; Wang Y; Ai Z; Ma L; Zhang Y; Hu L; Yang Q; Li J; Zhao S; Zhang Z; Teng Y
Oncogene; 2018 May; 37(18):2394-2409. PubMed ID: 29429992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
